Check for updates

The impact of immune-related adverse events on the outcome of advanced gastric cancer patients with immune checkpoint inhibitor treatment

Tianhang Zhang[1†], Haitao Lv[2†], Jiasong Li[1], Shasha Zhang[1], Jingjing Zhang[1], Siqi Wang[1], Yingnan Wang[1,3]* and Zhanjun Guo[1]*

[1]Department of Rheumatology and Immunology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China, [2]Department of Hepatobiliary Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, China, [3]Department of Gastroenterology and Hepatology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China

Background: The occurrence of immune-related adverse events (irAEs) seemed to be associated with better outcomes in advanced gastric cancer (AGC) patients. However, research focusing on the impact of the single-organ irAE (uni-irAE) or multi-organ irAEs (multi-irAEs) on the AGC outcome is relatively limited. In this study, we investigated individually the impact of the different irAEs on AGC survival as well as the co-occurrence patterns of multi-irAEs.

Methods: The uni-irAE, multi-irAEs, and non-irAE were identified based on National Comprehensive Cancer Network (NCCN) guidelines. ICI efficacy for the disease control rate (DCR) and the objective response rate (ORR) was assessed based on the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. The association for the irAEs with progression-free survival (PFS) or overall survival (OS) was analyzed using the Kaplan−Meier method and Cox regression model. We also performed pairwise correlation analysis to identify co-occurrence patterns of multi-organ irAEs.

Results: A total of 288 patients including 175 non-irAE, 73 uni-irAE, and 40 multi-irAE patients were evaluated for their association with AGC outcome. The irAEs patients displayed higher DCR (78.8% vs. 67.4%, $p=0.037$) when compared with those of non-irAE patients, and both uni-irAE patients (82.2% vs. 67.4%, $p=0.019$) and multi-irAE patients (72.5% vs. 67.4%, $p=0.534$) showed higher DCR than that of non-irAE patients. The multivariate analyses revealed that multi-irAEs was an independent risk factor for PFS (hazard ratio [HR] of 0.63, 95% confidence interval [CI] 0.41~0.96, $p=0.031$) and OS (HR 0.47, 95% CI 0.29~0.76, $p=0.002$), whereas the survival association for uni-irAE was not obtained. The analysis of the co-occurrence patterns for multi-irAEs revealed that the thyroid, adrenal gland, heart, skin, and lung irAEs exhibited a high risk of co-occurrence of multi-irAEs. The multivariate Cox regression analysis for organ-specific irAEs revealed that patients experiencing thyroid, adrenal gland, and skin irAEs had favorable survival outcomes compared with those without these irAEs.

Conclusion: Multi-irAEs and some organ-specific irAEs can be used as predictive indicators for ICI treatment efficacy in AGC patients. The thyroid, adrenal gland, heart, skin, and lung irAEs are often accompanied by multi-irAE occurrence.

Introduction

According to GLOBOCAN 2022, gastric cancer (GC) accounted for the fifth incidence with 968,000 novel cases and the fifth mortality with approximately 659,000 deaths among all malignant tumors (1). China is a high-risk area for GC with a crude incidence rate of 254.1 per 100,000 and a crude mortality rate of 184.4 per 100,000 (1, 2). Due to the atypical early symptoms of GC, most patients are already in the advanced stage when diagnosed (3). There are several available options for advanced gastric cancer (AGC) treatment such as systemic chemotherapy, targeted therapies, and immunotherapy (4). The National Comprehensive Cancer Network (NCCN) guidelines recommend a systemic chemotherapy regimen based on platinum combined with fluoropyrimidine drugs (5). Even with conventional chemotherapy, the survival probability for AGC is still less than 1 year (6). Although molecular targeted therapies, such as targeting human epidermal growth factor receptor 2 (HER2), vascular endothelial growth factor receptor 2 (VEGFR-2), and Claudin18.2, have achieved treatment improvement in recent years, not all patients' tumor cells have specific targets (7). Thus, chemotherapy and molecular targeted therapy have a limited impact on the overall prognosis of AGC. The advent of immunotherapy particularly immune checkpoint inhibitors (ICIs)

has revolutionized the treatment landscape in recent years (8). The Food and Drug Administration (FDA) has approved a number of anti-PD-1 antibodies for tumor treatment (9). Based on various phase III clinical trials, such as ATTRACTION-2 phase III, CheckMate-649, ORIENT-16, RATIONALE-305, and KEYNOTE-859, anti-PD-1 antibodies have transitioned from a third-line option to a first-line treatment in AGC patients (4, 10–16). ICI treatment significantly gives an improved overall prognosis for AGC patients by enhancing the host's endogenous immune response against the tumor (8).

The surveillance mechanisms of the host immune system play an important role in eliminating cancer, whereas tumors can express inhibitory signal molecules to suppress the immune function so as to achieve immune evasion via binding to their receptors on lymphocytes in the tumor microenvironment (TME) (17). These inhibitory signal molecules and their corresponding receptors are commonly referred to as immune checkpoints including programmed cell death-1 (PD-1), programmed cell death ligand-1 (PD-L1), and cytotoxic T lymphocyte-associated 4 (CTLA-4) (18). ICIs work by blocking immune checkpoints to restore the ability of the lymphocytes for tumor elimination (18).

However, the response to ICIs varies significantly among patients, leading to a hot research area for predicting individual responses (19–21). Previous studies have found that the appearance of immune-related adverse events (irAEs) may serve as a predictive indicator of good treatment outcomes (22–27).

IrAEs occur from weeks to months after initiation of ICIs, affecting various organs and tissues such as the skin, gastrointestinal system, lungs, liver, adrenal gland, and thyroid with a single organ involved or multiple organs involved (8). Some irAEs such as immune-related pneumonia, myocarditis, and enteritis can be fatal if they are not handled timely (28, 29). Based on the number of affected organs, irAEs can be categorized as "single-organ irAE (uni-irAE)" (affecting only one organ) and "multi-organ irAEs (multi-irAEs)" (affecting more than one organ) (23). Potential mechanisms for the development of irAEs include the common antigen between malignant cells and normal cells, the cross-immune response, off-target effects, B-cell activation and antibody-mediated damage, inflammatory cytokine-mediated damage, and the loss of peripheral tolerance in T cells caused by dysfunction of immune inhibitory cells (30–32). The occurrence of irAEs may signify the activation of the immune system, leading to continued attacks on tumor cells and causing sustained regression

Abbreviations: IrAEs, immune-related adverse events; AGC, advanced gastric cancer; uni-irAE, single-organ irAE; multi-irAEs, multi-organ irAEs; DCR, disease control rate; ORR, objective response rate; PFS, progression-free survival; OS, overall survival; GC, gastric cancer; HER2, human epidermal growth factor receptor 2; VEGFR-2, vascular endothelial growth factor receptor 2; TME, tumor microenvironment; PD-1, programmed cell death protein 1; PD-L1, programmed cell death ligand 1; CTLA-4, cytotoxic T lymphocyte-associated 4; ICIs, immune checkpoint inhibitors; FDA, Food and Drug Administration; SCLC, small cell pulmonary cancer; ECOG, Eastern Cooperative Oncology Group; TNM, tumor-node-metastasis; MMR, microsatellite mismatch repair; CTCAE, Common Terminology Criteria for Adverse Events; CT, computed tomography; MRI, magnetic resonance imaging; RECIST, Response Evaluation Criteria in Solid Tumors; CR, complete response; PR, partial response; PD, progression disease; SD, stable disease; CI, confidence interval; HR, hazard ratio; OR, odds ratio; LASSO, least absolute shrinkage and selection operator; IL-7, interleukin-7; IFN-γ, interferon gamma; IL-2, interleukin-2; IL-4, interleukin-4; IL-6, interleukin-6; IL-10, interleukin-10; TNF-α, tumor necrosis factor alpha; miRNAs, microRNAs.

of the tumor. Previous studies have found that the emergence of irAEs was recognized as a key indicator of improved effectiveness of ICI treatment in various tumor types, including melanoma and small cell lung cancer (SCLC) (22, 23, 33, 34). We and other researchers also revealed that the irAEs were associated with better OS and PFS in AGC patients (25, 27, 35).

However, the impact of irAEs on the treatment efficiency remains uncertain in AGC patients, so it does for the co-occurrence patterns of multi-irAEs (34). Therefore, we evaluated the impact of the occurrence of irAEs including uni-irAE, multi-irAEs, and organ-specific irAE on both the therapeutic efficacy and prognosis of AGC patients with ICI treatment in the present study. The specific co-occurrence patterns of irAEs across multiple organs and their prognostic implications were also evaluated.

Methods

Patients

This retrospective study containing 288 AGC patients who received anti-PD-1 antibodies (sintilimab, tislelizumab, camrelizumab, pembrolizumab, nivolumab, toripalimab, or serplulimab) as monotherapy or combination therapy (combined with chemotherapy, targeted drugs, or both) in the Fourth Hospital of Hebei Medical University between June 2019 and December 2023.

The inclusion criteria were as follows (1): histopathology confirmed adenocarcinoma GC before treatment initiation; (2) advanced unresectable tumor according to the American Joint Committee on Cancer criteria 8th (36); (3) patients who received PD-1 monotherapy or combination therapy; (4) no pertinent infections, nor any signs of acute or chronic inflammation, were observed before commencing treatment; (5) Eastern Cooperative Oncology Group (ECOG) score ≤2; (6) at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (37); (7) complete pathological and survival data were collected; (8) the patient's age was over 28 years old. The exclusion criteria were as follows: (1) patients combined with other tumor history or blood system diseases; (2) pathological types other than adenocarcinoma; (3) ECOG score ≥3 or multiple organ failure; (4) patients combined with autoimmune diseases before treatment; (5) patients who were allergic to the ingredients of PD-1.

The clinical characteristics including age, gender, ECOG score, tumor node metastasis (TNM) stage, family history, treatment lines, tumor site, tumor differentiation, treatment regimen, number of metastases, HER2 status, microsatellite mismatch repair (MMR) status, and PD-L1 expression were collected for analysis. All procedures were conducted in line with the Helsinki Declaration of 1964 and its later amendments and have been reviewed and sanctioned by the Ethics Committee of the Fourth Hospital of Hebei Medical University. Due to the retrospective design of the study, the requirement for informed consent was waived.

Evaluation and classification of irAEs

The classification and grading system of irAEs are based on the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE), version 5.0 (CTCAE_v5_Quick _Reference_8.5x11.pdf (cancer.gov)). They were identified by physicians or pharmacists. The inclusion criteria were as follows: (1) the emergence of adverse events after initiation of immunotherapy; (2) pathological test results (if available); (3) diagnosed based on baseline disease status; (4) clinical improvement following irAE targeting therapies. The exclusion criteria were as follows: (1) the exclusion of other potential diagnoses with similar clinical manifestations; (2) determined by physicians that the adverse reaction is not caused by other medications (such as chemotherapy). IrAEs were classified based on the organ system affected (such as the skin, gastrointestinal tract, lungs, endocrine system, musculoskeletal system, kidneys, liver, nervous system, hematological system, and eyes). IrAEs were graded according to CTCAE and ranged from grade 1 to grade 5, which referred to mild, moderate, severe, life-threatening, or fatal events, depending on the severity of symptoms and the support of certain serum biomarkers. We defined irAEs affecting only a single organ as "uni-irAE" and those involving more than two organs as "multi-irAEs". Consequently, the patients were categorized into three groups: those without any irAEs (non-irAE), those with uni-irAE, and those with multi-irAEs. Additionally, we used another classification method: each organ-specific irAE patients vs. other patients (including all the patients except the corresponding organ-specific irAE patients) to evaluate the ICI treatment efficacy for each organ-specific irAE.

Treatment efficiency assessment and follow-up

Patients received anti-PD-1 antibodies (monotherapy or combination therapy [combined with chemotherapy, targeted drugs, or both]) every 21 days until disease progression, clinical deterioration, unacceptable toxicity, or patient refusal. Body computed tomography (CT) scans or magnetic resonance imaging (MRI) scans were taken every 2–3 cycles to evaluate objective tumor response according to the RECIST Version 1.1 (37). Complete response (CR) was characterized by the total disappearance of the target lesion following treatment, whereas partial response (PR) referred to a decrease of 30% or more in the total diameter of each target lesion. Progressive disease (PD) was indicated by a minimum 20% increase in the sum of the long diameters of all target lesions, accompanied by an increase of more than 5 mm or the development of new lesions. Stable disease (SD) was defined as no change in the size of target lesions. The objective response rate (ORR) represented the proportion of patients exhibiting either a CR or PR out of all patients who received treatment. The disease control rate (DCR) reflected the percentage of patients achieving a CR, PR, or SD.

All patients were monitored through re-hospitalization, outpatient clinic visits, and telephone follow-ups until death or loss of contact for any reason. PFS was defined as the period from treatment initiation to the date of disease progression, death, or study cutoff. OS was defined as the time from treatment initiation to death from any cause or study cutoff. The end point of follow-up was 1 June 2024 or the date of death.

Statistical analysis

Statistical analyses were performed using SPSS version 27.0 software (IBM Corp., Armonk, NY, USA) and GraphPad Prism software (version 9.5, GraphPad Software, San Diego, CA, USA). Differences between the groups were compared using Pearson's chi-squared test or Fisher's exact test for categorical variables. Survival analysis for irAEs patients was evaluated using the Kaplan–Meier method with the log-rank test. Univariate and multivariate survival analyses were performed using the Cox proportional hazard model to evaluate the impact of the occurrence of irAEs. Univariate and multivariate logistic regression analyses were performed to evaluate risk factors for the occurrence of multi-irAEs. Univariate regression logistic analyses were performed to determine the association between each organ-specific irAE and multi-irAEs' development. The time to the onset of irAEs between the two groups was assessed using the Mann–Whitney U test. Both univariate and multivariate Cox proportional hazard model analyses for outcomes (OS and PFS) were only performed for each organ-specific irAE with a case number of more than 10 patients. The differences were considered statistically significant when the p-value was less than 0.05.

Results

IrAEs mediate treatment efficacy of ICIs

A total of 288 AGC patients were involved with anti-PD-1 antibodies administering including sintilimab, tislelizumab, camrelizumab, pembrolizumab, nivolumab, toripalimab, and serplulimab (Supplementary Table S1). Among these patients, 5 patients received ICI monotherapy, 209 patients received a combination of ICI and chemotherapy, 30 patients received a combination of ICI and targeted therapy, and 44 patients received a triple regimen of ICI, chemotherapy and targeted therapy (Supplementary Table S1).

These patients were classified as 175 (60.76%) of non-irAE, 73 (25.35%) of uni-irAE, and 40 (13.89%) of multi-irAEs. The patients' baseline characteristics are shown in Table 1; no significant difference was observed among the non-irAE group, uni-irAE group, and multi-irAEs group in terms of age, gender, ECOG score, TNM stage, family history, treatment lines, tumor site, tumor differentiation, treatment regimen, number of metastases, HER2 status, MMR status, and PD-L1 expression.

The overall DCR of PD-1 treatment was 71.9% (288 patients), with 67.4% (118 patients) in the non-irAE group and 78.8% (89 patients) in the irAE group. As shown in Table 2, the DCR was

significantly higher in the irAE group (p=0.037), uni-irAE group (p=0.019), and multi-irAE group (p=0.534) when compared with those of the non-irAE group, but no statistical difference existed between uni-irAE and multi-irAE group. These data demonstrated that the irAEs increased the DCR of AGC patients. Despite the multi-irAE group exhibiting a trend of ORR advantage, no statistical difference could be achieved.

The median PFS in the non-irAE, uni-irAE, and multi-irAEs group were 5.23 months (95% confidence interval [CI]: 4.42~6.05 months), 7.80 months (95% CI: 5.47~10.13 months), and 9.30 months (95% CI: 7.44~11.16 months), respectively (Table 3). The Kaplan–Meier curves of PFS and OS are presented in Figure 1, the multi-irAE group exhibited a substantial increase for median PFS (p=0.023) when compared with the non-irAE group, and no significant difference for PFS was identified between uni-irAE and multi-irAE groups (p=0.125), and no statistical difference between the non-irAE and uni-irAE groups was observed (p=0.246) either. The multivariate Cox proportional hazard model identified multi-irAEs as an independent prognostic factor for PFS (hazard ratio [HR]: 0.63, 95% CI: 0.41~0.96, p=0.031). Other characteristics such as age (HR 0.41, 95% CI 0.24~0.68, p<0.001 for those aged 45–65 years; HR 0.44, 95% CI 0.26~0.74, p=0.002 for those aged>65 years), ECOG score (HR 1.63, 95% CI 1.24~2.14, p<0.001), and treatment line (HR 1.87, 95% CI 1.40~2.48, p<0.001) were also identified as independent risk factors of PFS (Table 4). These data demonstrated that the occurrence of multi-irAEs was associated with better PFS.

The median OS in the non-irAE, uni-irAE, and multi-irAE groups were 11.43 months (95% CI: 9.16~13.70 months), 14.20 months (95% CI: 13.14~15.26 months), and 19.50 months (95% CI: 3.75~35.25 months), respectively (Table 3). The median OS of multi-irAEs displayed a significant extension compared with that of the non-irAE group (p<0.001); the uni-irAE group also showed an extended median OS than that of the non-irAE group (p=0.029), but no significant difference existed between the uni-irAE and multi-irAE groups (p=0.124). The multivariate Cox proportional hazard model indicated that multi-irAEs was an independent prognostic factor for OS (HR 0.47, 95% CI 0.29~0.76, p=0.002). In addition, age (HR 0.41, 95% CI 0.24~0. 71, p=0.001 for those aged 45–65 years, HR 0.47, 95% CI 0.27~0.80, p=0.006 for those aged >65 years), ECOG score (HR 1.57, 95% CI 1.18~2.11, p=0.002), TNM stage (HR 1.46, 95% CI 1.01~2.11, p=0.043), and treatment line (HR 1.74, 95% CI 1.30~2.34, p< 0.001) remained as independent prognostic factors for OS (Table 5). All these results indicated that multi-irAEs modify the treatment efficiency of ICI by increasing DCR, PFS, and OS.

Co-occurrence pattern analysis for multi-irAEs

The most common irAEs in the uni-irAE group was hypothyroidism or hyperthyroidism (27.40%), whereas the common types of co-occurrence multi-irAEs were skin plus adrenal gland (15.00%), thyroid plus adrenal gland (12.50%), and thyroid plus heart (12.50%) (Supplementary Table S2). Among the multi-irAE group, 14 cases (35.00%) co-occurred simultaneously,

TABLE 1 The baseline clinical characteristics of non-irAE, uni-irAE, and multi-irAE groups in AGC patients.

Variable	Non-irAE group No.(%)	Uni-irAE group No.(%)	Multi-irAEs group No.(%)	p-value
Gender				0.107
Female	38 (21.71)	25 (34.25)	9 (22.50)	
Male	137 (78.29)	48 (65.75)	31 (77.50)	
Age				0.613
18-44	15 (8.57)	3 (4.11)	2 (5.00)	
45-65	79 (45.14)	39 (53.42)	19 (47.50)	
>65	81 (46.29)	31 (42.47)	19 (47.50)	
ECOG				0.889
≤1	105 (60.00)	46 (63.01)	25 (62.50)	
>1	70 (40.00)	27 (36.99)	15 (37.50)	
TNM				0.611
III	42 (24.00)	21 (28.77)	12 (30.00)	
IV	133 (76.00)	52 (71.23)	28 (70.00)	
Family history				0.56
No	132 (75.43)	58 (79.45)	33 (82.50)	
Yes	43 (24.57)	15 (20.55)	7 (17.50)	
Tumor site				0.913
Non-cardia cancer	77 (44.00)	30 (41.10)	17 (42.50)	
Cardia cancer	98 (56.00)	43 (58.90)	23 (57.50)	
Tumor differentiation				0.665
Medium to high	57 (32.57)	28 (38.36)	13 (32.50)	
Low	118 (67.43)	45 (61.64)	27 (67.50)	
Treatment line				0.104
1	109 (62.29)	48 (65.75)	32 (80.00)	
>1	66 (37.71)	25 (34.25)	8 (20.00)	
Treatment regimen				0.112
ICI	1 (0.57)	2 (2.74)	2 (5.00)	
ICI plus chemotherapy	128 (73.14)	55 (75.34)	26 (65.00)	
ICI plus targeted therapy	16 (9.14)	6 (8.22)	8 (20.00)	
ICI plus chemotherapy and targeted therapy	30 (17.14)	10 (13.70)	4 (10.00)	
Number of metastases				0.08
≤1	113 (64.57)	47 (64.38)	33 (82.50)	
>1	62 (35.43)	26 (35.62)	7 (17.50)	
HER2				0.16
Negative	81 (46.29)	30 (41.10)	26 (65.00)	
Positive	84 (48.00)	38 (52.05)	12 (30.00)	
Unknown	10 (5.71)	5 (6.85)	2 (5.00)	

(Continued)

TABLE 1   Continued

Variable	Non-irAE group No.(%)	Uni-irAE group No.(%)	Multi-irAEs group No.(%)	p-value
MMR				0.224
Negative	144 (82.29)	57 (78.08)	28 (70.00)	
Positive	3 (1.71)	2 (2.74)	3 (7.50)	
Unknown	28 (16.00)	14 (19.18)	9 (22.50)	
PD-L1				0.255
Negative	41 (23.43)	23 (31.51)	9 (22.50)	
Positive	113 (64.57)	39 (53.42)	22 (55.00)	
Unknown	21 (12.00)	11 (15.07)	9 (22.50)	

IrAEs, immune-related adverse events; Uni-irAE, single-organ irAE; multi-irAEs, multi-organ irAEs; AGC, advanced gastric cancers; ECOG, Eastern Cooperative Oncology Group; TNM, tumor-node-metastasis; MMR, microsatellite mismatch repair HER2, human epidermal growth factor receptor-2; PD-L1, programmed cell death ligand 1.
The bold texts represents the grouping names for clinical characteristics.

whereas the remaining occurred sequentially. Univariate logistic regression analyses were performed to evaluate the co-occurrence pattern of multi-irAEs (Table 6), and the results showed that the thyroid, adrenal gland, heart, skin, and lung irAEs were more likely to develop multi-irAEs (odds ratio [OR] 2.40, 95% CI 1.07~5.37, p=0.033 for thyroid irAEs; OR 3.08, 95% CI 1.29~7.36, p=0.011 for adrenal gland irAEs; OR 3.72, 95% CI 1.24~11.18, p=0.019 for heart irAEs; OR 2.43, 95% CI 1.06~5.58, p=0.035 for skin irAEs; OR 4.31, 95% CI 1.21~15.38, p=0.024 for lung irAEs). The remaining gastrointestinal system, hematological system, liver, kidney, and musculoskeletal system irAEs are not related to the occurrence of multi-irAEs (all p>0.05).

The association between patients' characteristics and multi-irAEs was performed by univariate and multivariate logistic regression analyses, and only those who were HER2 positive were less likely to experience multi-irAEs (OR 0.39, 95% CI 0.17~0.92, p=0.031) (Supplementary Table S3).

Timepoint of irAE onset

The onset time of each irAE is shown in Figure 2; the median time points of the five irAEs associated with co-occurrence of multi-irAEs were 3.03 months for thyroid irAE, 5.20 months for adrenal gland irAE, 1.90 months for heart irAE, 2.95 months for skin irAE, and 5.22 months for lung irAE. The onset of heart irAE with high morbidity and mortality was the mostly earliest among these all types. The median occurrence timepoint of the same irAE between uni-irAE and multi-irAEs groups was compared, and no statistical difference for each irAE between the two groups (Figure 2). These

TABLE 2   Response to ICI of irAEs, non-irAE, uni-irAE, and multi-irAE groups in AGC patients.

Comparison	PD	SD	PR	CR	DCR	p-value (DCR)	ORR	p-value (ORR)
Non-irAE group vs. irAE group						0.037		0.750
Non-irAE group	57	87	31	0	67.4%		17.7%	
irAE group	24	71	17	1	78.8%		15.9%	
Uni-irAE group vs. multi-irAE group						0.228		0.381
Uni-irAE group	13	50	10	0	82.2%		13.7%	
Multi-irAE group	11	21	7	1	72.5%		20.0%	
Non-irAE group vs. uni-irAE group						0.019		0.438
Non-irAE group	57	87	31	0	67.4%		17.7%	
Uni-irAE group	13	50	10	0	82.2%		13.7%	
Non-irAE group vs. multi-irAE group						0.534		0.735
Non-irAE group	57	87	31	0	67.4%		17.7%	
Multi-irAE group	11	21	7	1	72.5%		20.0%	

IrAEs, immune-related adverse events; Uni-irAE, single-organ irAE; Multi-irAEs, multi-organ irAEs; AGC, advanced gastric cancers; SD, stable disease; PR, partial response; PD, progressive disease; CR, complete response; ORR, objective response rate; DCR, disease control rate.
The bold texts represents the grouping names for clinical characteristics.

TABLE 3 Median PFS and OS of non-irAE, uni-irAE, and multi-irAE groups in AGC patients.

Covariate	Median PFS (95% CI) (months)	p-value (Log-rank)	Median OS (95% CI) (months)	p-value (Log-rank)
Non-irAE group vs. Uni-irAE group		0.246		0.029
Non-irAE group	5.23 (4.42~6.05)		11.43 (9.16~13.70)	
Uni-irAE group	7.80 (5.47~10.13)		14.20 (13.14~15.26)	
Non-irAE group vs. Multi-irAE group		0.023		< 0.001
Non-irAE group	5.23 (4.42~6.05)		11.43 (9.16~13.70)	
Multi-irAE group	9.30 (7.44~11.16)		19.50 (3.75~35.25)	
Uni-irAE group vs. Multi-irAE group		0.125		0.124
Uni-irAE group	5.23 (4.42~6.05)		14.20 (13.14~15.26)	
Multi-irAE group	9.30 (7.44~11.16)		19.50 (3.75~35.25)	

IrAEs, immune-related adverse events; Uni-irAE, single-organ irAE; Multi-irAEs, multi-organ irAEs; AGC, advanced gastric cancers; OS, overall survival; PFS, progression-free survival.
The bold texts represents the grouping names for clinical characteristics.

data implied that the time extension was not associated with the occurrence of multi-irAEs.

The impact of each organ-specific irAE on ICI treatment

We performed the treatment efficacy and prognosis analysis for all organ-specific irAEs. The thyroid irAE displayed higher DCR than that of the other group (87.2% vs. 69.5%, $p=0.022$), but no association with DCR or ORR could be found for the remaining organ-specific irAEs (Supplementary Table S4). As shown in Supplementary Table S5 and Supplementary Figure S1, only the thyroid and adrenal gland irAE exhibited a significant increase for median PFS when compared individually with the others group (thyroid: 11.37 months [95% CI: 7.20~15.54] vs. 5.77 months [95% CI: 4.81~6.73], $p=0.023$; adrenal gland: 10.23 months [95% CI: 8.26~12.21] vs. 5.83 months [95% CI: 4.92~6.75], $p=0.006$) by the Kaplan–Meier method with the log-rank test. The multivariate survival analysis indicated that the thyroid and adrenal gland irAEs were independent risk factors for extending PFS (thyroid: HR 0.65, 95% CI 0.44~0.96, $p=0.031$; adrenal gland: HR 0.50, 95% CI 0.30~0.83, $p=0.008$) (Supplementary Tables S8, S9). Furthermore, the thyroid, adrenal gland, and skin irAE patients exhibited a substantial increase for median OS comparing with the

other groups (thyroid: 24.43 months [95% CI: 9.61~39.25] vs. 12.27 months [95% CI: 10.75~13.78], $p=0.004$; adrenal gland: 16.30 months [95% CI: 14.70~NA] vs. 12.27 months [95% CI: 11.05~13.48], $p=0.003$; skin: 17.37 months [95% CI: 14.36~20.37] vs. 12.40 months [95% CI: 10.99~13.81], $p=0.016$) (Supplementary Table S5, Supplementary Figure S1). The multivariate survival analysis indicated that the thyroid, adrenal gland, and skin irAEs were independent risk factors for extending OS (thyroid: HR 0.53, 95% CI 0.34~0.84, $p=0.007$; adrenal gland: HR 0.47, 95% CI 0.26~0.85, $p=0.012$; skin: HR 0.58, 95% CI 0.35~0.97, $p= 0.039$) (Supplementary Tables S10-S12). No statistically significant impact on PFS or OS was observed for heart and lung irAEs (all $p>0.05$) (Supplementary Tables S6, S7).

Discussion

The occurrence of irAEs seemed to be a good predictor for ICI treatment in many cancer types including GC patients (25, 27, 38, 39). The occurrence of irAEs is linked with better DCR and prolonged OS and PFS in AGC patients with nivolumab monotherapy; we also found that irAEs were associated with prolonged PFS in AGC patients, but few studies focus on the association of uni-irAE or multi-irAEs with the outcome of AGC patients (27, 40, 41). In the present study, the


FIGURE 1
The Kaplan–Meier curve of progression-free survival (PFS) and overall survival (OS) of all patients.

TABLE 4 Univariate and multiple Cox proportional hazard models on PFS in AGC patients.

Covariate	Univariate analysis			Multivariate analysis		
	HR	95% CI	*p*-value	HR	95% CI	*p*-value
Gender						
Female	1.00 (reference)					
Male	0.85	0.63~1.14	0.278			
Age						
18-44	1.00 (reference)			1.00 (reference)		
45-65	0.53	0.32~0.87	0.013	0.41	0.24~0.68	<.001
>65	0.49	0.30~0.81	0.006	0.44	0.26~0.74	0.002
ECOG						
≤1	1.00 (reference)			1.00 (reference)		
>1	1.71	1.31~2.22	<.001	1.63	1.24~2.14	<.001
TNM						
III	1.00 (reference)			1.00 (reference)		
IV	1.51	1.11~2.04	0.008	1.29	0.94~1.76	0.120
Family history						
No	1.00 (reference)					
Yes	1.02	0.75~1.39	0.875			
Tumor site						
Non-cardia cancer	1.00 (reference)					
Cardia cancer	1.03	0.79~1.33	0.846			
Tumor differentiation						
Medium to high	1.00 (reference)					
Low	1.00	0.76~1.31	0.982			
Treatment line						
1	1.00 (reference)			1.00 (reference)		
>1	1.90	1.46~2.48	<.001	1.87	1.40~2.48	<.001
Treatment regimen						
I	1.00 (reference)					
I+C	1.56	0.50~4.89	0.446			
I+T	2.93	0.89~9.67	0.077			
I+C+T	2.39	0.74~7.73	0.147			
Number of metastases						
≤1	1.00 (reference)					
>1	1.17	0.89~1.53	0.267			
HER2						
Negative	1.00 (reference)			1.00 (reference)		
Positive	0.76	0.58~0.99	0.046	0.80	0.60~1.05	0.108
Unknown	0.62	0.35~1.09	0.099	0.69	0.35~1.33	0.265

(Continued)

TABLE 4 Continued

Covariate	Univariate analysis			Multivariate analysis		
	HR	95% CI	*p*-value	HR	95% CI	*p*-value
MMR						
Negative	1.00 (reference)			1.00 (reference)		
Positive	0.35	0.13~0.95	0.038	0.47	0.17~1.31	0.150
Unknown	1.00	0.72~1.40	0.989	1.04	0.69~1.56	0.861
PD-L1						
Negative	1.00 (reference)			1.00 (reference)		
Positive	0.70	0.52~0.95	0.021	0.74	0.54~1.03	0.074
Unknown	0.89	0.59~1.35	0.578	0.91	0.55~1.50	0.701
irAE						
Non-	1.00 (reference)			1.00 (reference)		
Uni-	0.84	0.62~1.13	0.248	0.86	0.63~1.17	0.324
Mul-	0.60	0.40~0.91	0.015	0.63	0.41~0.96	0.031

IrAEs, immune-related adverse events; Uni-irAE, single-organ irAE; Multi-irAEs, multi-organ irAEs; AGC, advanced gastric cancer; HR, hazard ratio; CI, confidence interval; PFS, progression-free survival; ECOG, Eastern Cooperative Oncology Group; TNM, tumor-node-metastasis; MMR, microsatellite mismatch repair HER2, human epidermal growth factor receptor-2; PD-L1, programmed cell death ligand 1.

TABLE 5 Univariate and multiple Cox proportional hazard model on OS in AGC patients.

Covariate	Univariate analysis			Multivariate analysis		
	HR	95% CI	*p*-value	HR	95% CI	*p*-value
Gender						
Female	1.00 (reference)					
Male	0.98	0.71~1.35	0.885			
Age						
18-44	1.00 (reference)			1.00 (reference)		
45-65	0.47	0.28~0.79	0.004	0.41	0.24~0.71	0.001
>65	0.47	0.28~0.79	0.005	0.47	0.27~0.80	0.006
ECOG						
≤ 1	1.00 (reference)			1.00 (reference)		
>1	1.66	1.25~2.21	<.001	1.57	1.18~2.11	0.002
TNM						
III	1.00 (reference)			1.00 (reference)		
IV	1.7	1.19~2.42	0.003	1.46	1.01~2.11	0.043
Family history						
No	1.00 (reference)					
Yes	1.04	0.74~1.45	0.842			
Tumor site						
Non-cardia cancer	1.00 (reference)					
Cardia cancer	0.92	0.69~1.23	0.583			

(Continued)

TABLE 5 Continued

Covariate	Univariate analysis			Multivariate analysis		
	HR	95% CI	*p*-value	HR	95% CI	*p*-value
Tumor differentiation						
Medium to high	1.00 (reference)					
Low	1.02	0.76~1.39	0.874			
Treatment line						
1	1.00 (reference)			1.00 (reference)		
>1	1.9	1.42~2.53	<.001	1.74	1.30~2.34	<.001
Treatment regimen						
I	1.00 (reference)					
I+C	0.98	0.31~3.08	0.972			
I+T	1.49	0.45~4.95	0.516			
I+C+T	1.45	0.45~4.75	0.535			
Number of metastases						
≤1	1.00 (reference)					
>1	1.13	0.84~1.52	0.426			
HER2						
Negative	1.00 (reference)					
Positive	0.79	0.59~1.06	0.117			
Unknown	0.72	0.39~1.32	0.284			
MMR						
Negative	1.00 (reference)					
Positive	0.52	0.19~1.41	0.199			
Unknown	0.91	0.63~1.32	0.631			
PD-L1						
Negative	1.00 (reference)					
Positive	0.84	0.60~1.17	0.301			
Unknown	0.84	0.53~1.33	0.456			
irAE						
Non-	1.00 (reference)			1.00 (reference)		
Uni-	0.68	0.48~0.96	0.027	0.76	0.53~1.07	0.117
Mul-	0.43	0.27~0.70	<.001	0.47	0.29~0.76	0.002

IrAEs, immune-related adverse events; Uni-irAE, single-organ irAE; Multi-irAEs, multi-organ irAEs; AGC, advanced gastric cancer; HR, hazard ratio; CI, confidence interval; OS, overall survival; ECOG, Eastern Cooperative Oncology Group; TNM, tumor-node-metastasis; MMR, microsatellite mismatch repair HER2, human epidermal growth factor receptor-2; PD-L1, programmed cell death ligand 1.

multivariate analysis proved the association with both PFS and OS for multi-irAE AGC patients. Although the PFS extension of uni-irAE did not show statistical difference probably due to the small sample size, it displayed both the better DCR and the extension of OS in univariate analysis compared with the non-irAE group. Multiple centers with larger sample sizes are needed to confirm whether it is truly unrelated to PFS and OS. We also used the least absolute shrinkage and selection operator (LASSO) regression model suitable for small sample size

analysis to verify these results. Notably, the results derived from these models aligned consistently with our initial findings referring to the association between multi-irAE and treatment outcomes (data not shown). These results are consistent with the results from the advanced renal cell carcinoma and SCLC, which suggest that the occurrence of irAEs indicates better survival, and multi-irAE patients exhibited an improved survival time than those of uni-irAE or non-irAE patients [34].

TABLE 6 Univariate logistic regression analysis of the relationship between each organ-specific irAE and multi-irAEs in AGC patients.

Covariate	OR(95% CI)	p-value
Thyroid	2.40 (1.07~5.37)	0.033
Adrenal gland	3.08 (1.29~7.36)	0.011
Heart	3.72 (1.24~11.18)	0.019
Gastrointestinal system	1.40 (0.30~6.59)	0.671
Skin	2.43 (1.06~5.58)	0.035
Lung	4.31 (1.21~15.38)	0.024
Liver	1.92 (0.45~8.12)	0.377
Kidney	0.00 (0.00~Inf)	0.988
Hematological system	1.87 (0.25~13.79)	0.540
Musculoskeletal system	5.84 (0.59~58.09)	0.132

IrAEs, immune-related adverse events; Multi-irAEs, multi-organ irAEs; AGC, advanced gastric cancer; OR, odds ratio.

The precise mechanism underlying the enhanced efficacy of ICIs in patients with irAEs remains unclear, and few discussions regarding to the mechanism by which treatment efficacy of multi-irAEs is superior to uni-irAE. Functional experiments based on irAE-related experimental animals need to be performed to reveal the corresponding changes in the tumor microenvironment, including activated CD8, mature B cells, and even mature tertiary lymphoid structures, Treg cells, tumor associated macrophages, cytokines, etc.

One hypothesis for irAE-mediated prognosis posits that ICIs reactivate exhausted T cells with cross-reactivity to both tumor and normal tissue antigens, resulting in enhanced antitumor immunity and irAEs (42). However, some scholars also argue that the related immune response induced by ICIs may be non-specific, so it may attack both tumor and non-tumor cells indiscriminately (43). Another possible explanation is that the inflammatory cytokine involved in the occurrence of irAEs could modify the treatment efficiency in cancer patients, and the patients carrying genetic variations near the interleukin-7 (IL-7) gene may have both a higher incidence of irAEs and improved survival. The abnormal expression of IL-7 might increase the stability of lymphocytes as well as block PD-1 to create a more favorable microenvironment corresponding to the ICI treatment (44, 45). Another cytokine of interferon gamma (IFN-γ) also associated with both the occurrence of irAEs and better survival expectation (46–48). We had measured the blood cytokine levels of interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-6 (IL-6), interleukin-10 (IL-10), IFN-γ, and tumor necrosis factor alpha (TNF-α) between patients with and without irAEs, but no statistically significant differences were found (data not shown). We need to check other cytokines in the future. Thirdly, the gene mutations and expressing changes might be implicated in the occurrence of irAEs (44, 49); we conducted an expression profiling analysis for blood microRNAs (miRNAs) including 16 miRNAs, which were proved to modify the AGC outcome with ICI treatment, but no candidate miRNA could be identified for their association with irAE occurrence (data not shown). Fourthly, the gut microbiota species and their metabolic

pathway are involved in the occurrence of irAEs in GC patients; the gut microbiota species were also proved to enhance the treatment efficiency of ICI (50–52), so there is every chance that gut microbiota can mediate the irAE occurrence as well as modify the treatment efficiency. According to the above conjecture, the occurrence of irAEs and antitumor immunity may share common pathways to complete the immune response, which may involve various changes of the immune microenvironment upon treatment (26, 53). Therefore, we speculated that the multi-irAEs indicated a stronger immune response, or it induced a more altered immune microenvironment to better adapt to immunotherapy.

We conducted separate analyses of irAEs for each organ to elucidate the co-occurrence patterns, timing of onset, and impact on prognosis. To the best of our knowledge, our study represents the first comprehensive and detailed analysis of irAEs for each organ in AGC. We did not find correlations between the multi-irAEs and clinical characteristics with good prognosis prediction, such as age, ECOG score, and treatment lines. However, we found that heart, lung, skin, thyroid, and adrenal gland irAEs were associated with the co-occurrence of multi-organ irAEs. A previous retrospective study also revealed that skin irAEs and thyroid irAEs were associated with the co-occurrence of multi-irAEs in patients among multiple tumor types (34). According to our research data, it seems that thyroid plus adrenal gland irAE, thyroid plus heart irAE, thyroid plus skin irAE, or skin plus adrenal gland irAE are more common co-occurring combinations. One possible explanation for the co-occurrence of irAEs is that the adaptive immune system eliminates most of the high-affinity self-reactive cells (immune cells that can recognize and attack self-antigens) through a complex selection process. The leaving out of self-reactive cells after immune clearance will be activated during immunotherapy, and some overlooked immune cells may express different antibodies against self-antigens and attack the same self-antigens expressed in the different organs, thereby inducing the co-occurrence of irAEs (54). The anti-thyroglobulin IgG increased during the liver irAE, which can also initiate the thyroid irAE (8, 55). Another potential explanation is that ICI disrupts peripheral immune tolerance, thereby enabling immune cells to re-recognize specific harmless microorganisms or environmental proteins, potentially leading to irAEs in barrier organs such as skin and lungs (54). The true mechanism of co-occurrence of multi-irAEs is still controversial.

The onset of heart irAE with high morbidity and mortality was the mostly earliest among these irAEs, which may imply that early-onset irAEs might be more severe (56). Additionally, as the symptoms of skin irAEs can be easily identified without the need for laboratory tests, its onset may manifest at an earlier stage. However, there was no significant difference in the onset time of heart, lung, skin, thyroid, and adrenal gland irAEs between uni-irAE and multi-irAEs groups, which means that the occurrence of multi-irAE is unrelated to time. This is consistent with Yamaguchi's data in multiple tumor types (34).

As for the association of specific organ irAEs and the outcome of these AGC patients, we found that the thyroid and adrenal gland irAEs predict a longer survival period referring to PFS, whereas the thyroid, adrenal gland, and skin irAEs are associated with longer OS. Previous research also confirmed our finding regarding the thyroid, adrenal gland, and skin irAEs for their association with better treatment

FIGURE 2
(A) Time to onset of one-specific organ irAEs (median, range, and months). Time to onset of thyroid (B), adrenal gland (C), heart (D), skin (E), and lung (F) irAEs in uni-irAE and multi-irAE groups.

outcome in AGC and other cancer patients (57). They believed that skin, thyroid, and adrenal gland irAE were indicative of a robust immune response for the antitumor efficacy of ICI.

The possible reasons for the improvement in prognosis associated with skin irAEs are as follows: The skin is abundant of immune cells with the tissue-resident memory CD8 T cells being the primary type, which can initiate the immunologic reaction to eliminate tumor. In addition, the sensory nerve cell in the skin can secrete certain neuropeptides (such as substance P) to drive the expression of proinflammatory cytokines, thereby enhancing the responsiveness of immune cells for tumor clearance (58, 59). Although the specific

pathways underlying irAEs in the endocrine system are not yet fully understood, potential mechanisms may involve enhanced T-cell activation, autoantibody stimulation, and increased cytokine levels (57). The thyroid irAE-related genetic variations, which were identified by whole-genome sequencing in ICI-treated cancer patients, could modify the systemic immune response to PD-1 blockade (60). Additionally, thyroid and adrenal gland irAEs are generally less severe without intermittent treatment of ICI (61). Conversely, irAEs affecting heart, lungs, liver, and muscles often present with more severe symptoms or chronic persistence that need a large amount of glucocorticoids to suppress the immune response

with the intermittent treatment of ICI. This may partially explain why thyroid and adrenal gland irAE achieved better outcomes. The relationship between gastrointestinal system, lung, renal, and liver irAEs and prognosis are still controversial and mixed. Further investigation with larger sample sizes is needed in the future.

Given the above, these results highlight the clinical importance of identifying co-occurrence patterns of irAEs and support the specific monitoring, diagnosing, and managing for skin and endocrine irAEs, because they can be served as prognostic biomarkers for multi-organ irAEs.

This study has some limitations: 1. It was a retrospective observational cohort study performed at a single center with a relatively small size. Although the overall number of patients has basically met the requirement, the sample of patients experiencing single-organ irAEs was still small, although not for multi-organ irAEs. 2. Selection biases such as differences in patient treatment protocols and variations in lines of therapy might influence the final results. 3. The lack of diversity in the patient population. 4. A short follow-up period is also a limitation. However, irAE was originally an exclusionary diagnosis without definitive pathological evidence to rely on; more and more irAEs were recognized with the increasingly widespread application of immunotherapy, which may be one of the reasons for the relatively changed results referring to the impact of irAEs on ICI treatment efficiency. In the future, we need to carry out a larger sample size study with multicenter and multi-tumor species to further verify the value of irAEs in ICI treatment.

Conclusion

Multi-organ irAEs can be used as a predictive indicator for good efficacy in AGC patients with ICI treatment. The thyroid, adrenal gland, heart, skin, and pulmonary irAEs are often accompanied by the multi-organ irAE occurrence. The organ-specific irAEs for thyroid, adrenal gland, and skin were associated with better outcome. Early assessment of irAEs is crucial for patients for enhancing early monitoring and early preventive interventions.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

Ethics statement

The studies involving humans were approved by Fourth Hospital of Hebei Medical University (No.2024KS059). The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation was not required from the participants or the participants' legal guardians/next of kin in accordance with the national legislation and institutional requirements.

Author contributions

TZ: Formal analysis, Investigation, Writing – original draft. HL: Investigation, Supervision, Writing – original draft. JL: Data curation, Investigation, Resources, Software, Writing – original draft. SZ: Data curation, Investigation, Writing – original draft. JZ: Data curation, Supervision, Writing – original draft. SW: Data curation, Investigation, Writing – original draft. YW: Conceptualization, Supervision, Writing – review & editing. ZG: Conceptualization, Supervision, Writing – review & editing.

Funding

Acknowledgments

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declare that no Generative AI was used in the creation of this manuscript.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2024.1503316/full#supplementary-material

SUPPLEMENTARY TABLE 1
Treatment regimen of AGC patients.

SUPPLEMENTARY TABLE 2
The number of irAE cases and the timing of onset for uni-irAE and multi-irAEs groups in AGC patients.

SUPPLEMENTARY TABLE 3
Univariate and multivariate logistic regression analyses for the clinical characteristics associated with the occurrence of multi-irAEs in AGC patients.

SUPPLEMENTARY TABLE 4
Response rate analysis of each organ-specific irAE vs. other patients in AGC patients.

SUPPLEMENTARY TABLE 5
Median PFS and OS of each organ-specific group vs. other patients in AGC patients.

SUPPLEMENTARY TABLE 6
Univariate analysis for the clinical characteristics associated with PFS and OS in AGC patients (each organ-specific irAE with a case number of more than 10 patients was included in clinical characteristics for analysis).

SUPPLEMENTARY TABLE 7
Univariate analysis for the clinical characteristics associated with PFS and OS in AGC patients (each organ-specific irAE with a case number of more than 10 patients was included in clinical characteristics for analysis).

SUPPLEMENTARY TABLE 8
Multivariate Cox proportional hazard model analysis for the association between PFS and organ-specific irAEs in AGC patients.

SUPPLEMENTARY TABLE 9
Multivariate Cox proportional hazard model analysis for the association between PFS and organ-specific irAEs in AGC patients.

SUPPLEMENTARY TABLE 10
Multivariate Cox proportional hazard model analysis for the association between OS and organ-specific irAEs in AGC patients.

SUPPLEMENTARY TABLE 11
Multivariate Cox proportional hazard model analysis for the association between OS and organ-specific irAEs in AGC patients.

SUPPLEMENTARY TABLE 12
Multivariate Cox proportional hazard model analysis for the association between OS and organ-specific irAEs in AGC patients.

SUPPLEMENTARY FIGURE 1
(A.-J) The Kaplan–Meier curve of progression-free survival (PFS) and overall survival (OS) of each specific irAE with a case number of more than 10 patients in AGC patients. **(A)** PFS of thyroid irAE patients. **(B)** OS of thyroid irAE patients. **(C)** PFS of adrenal gland irAE patients. **(D)** OS of adrenal gland irAE patients. E: PFS of heart irAE patients. **(F)** OS of heart irAE patients. **(G)** PFS of skin irAE patients. **(H)** OS of skin irAE patients. I: PFS of lung irAE patients. **(J)** OS of lung irAE patients.

References

1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. (2024) 74:229–63. doi: 10.3322/caac.21834

2. He F, Wang S, Zheng R, Gu J, Zeng H, Sun K, et al. Trends of gastric cancer burdens attributable to risk factors in China from 2000 to 2050. *Lancet Reg Health - West Pac*. (2024) 44:101003. doi: 10.1016/j.lanwpc.2023.101003

3. Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. *Ann Oncol*. (2022) 33:1005–20. doi: 10.1016/j.annonc.2022.07.004

4. Lynch E, Duffy AG, Kelly RJ. Brave new world-new and emerging treatments for gastric cancer. *Chin Clin Oncol*. (2023) 12:54–4. doi: 10.21037/cco-23-13

5. Ajani JA, D'Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, et al. Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology. *J Natl Compr Canc Netw*. (2022) 20:167–92. doi: 10.6004/jnccn.2022.0008

6. Du J, Wei J, Yang Y, Su S, Shao J, Chen F, et al. Disappearance of bone metastases in chemotherapy-resistant gastric cancer treated with antigen peptide-pulsed dendritic cell-activated cytotoxic T lymphocyte immunotherapy: A case report. *Oncol Lett*. (2018) 16:875–81. doi: 10.3892/ol.2018.8781

7. Ratti M, Orlandi E, Toscani I, Vecchia S, Anselmi E, Hahne JC, et al. Emerging therapeutic targets and future directions in advanced gastric cancer: A comprehensive review. *Cancers*. (2024) 16:2692. doi: 10.3390/cancers16152692

8. Casagrande S, Sopetto GB, Bertalot G, Bortolotti R, Racanelli V, Caffo O, et al. Immune-related adverse events due to cancer immunotherapy: immune mechanisms and clinical manifestations. *Cancers*. (2024) 16:1440. doi: 10.3390/cancers16071440

9. Frey C, Etminan M. Adverse events of PD-1, PD-L1, CTLA-4, and LAG-3 immune checkpoint inhibitors: an analysis of the FDA adverse events database. *Antibodies*. (2024) 13:59. doi: 10.3390/antib13030059

10. Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. *Lancet*. (2021) 398:27–40. doi: 10.1016/S0140-6736(21)00797-2

11. Tabernero J, Bang Y-J, Van Cutsem E, Fuchs CS, Janjigian YY, Bhagia P, et al. KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma. *Future Oncol*. (2021) 17:2847–55. doi: 10.2217/fon-2021-0176

12. Xu J, Jiang H, Pan Y, Gu K, Cang S, Han L, et al. Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial. *JAMA*. (2023) 330:2064. doi: 10.1001/jama.2023.19918

13. Janjigian YY, Kawazoe A, Yañez P, Li N, Lonardi S, Kolesnik O, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. *Nature*. (2021) 600:727–30. doi: 10.1038/s41586-021-04161-3

14. Boku N, Ryu M-H, Kato K, Chung HC, Minashi K, Lee K-W, et al. Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4). *Ann Oncol*. (2019) 30:250–8. doi: 10.1093/annonc/mdy540

15. Sun J-M, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. *Lancet*. (2021) 398:759–71. doi: 10.1016/S0140-6736(21)01234-4

16. Hindson J. KEYNOTE-811: pembrolizumab in advanced HER2+ gastric cancer. *Nat Rev Gastro Hepat*. (2022) 19:79–9. doi: 10.1038/s41575-022-00577-y

17. Yoon J, Kim T-Y, Oh D-Y. Recent progress in immunotherapy for gastric cancer. *J Gastric Cancer*. (2023) 23:207. doi: 10.5230/jgc.2023.23.e10

18. Pauken KE, Dougan M, Rose NR, Lichtman AH, Sharpe AH. Adverse events following cancer immunotherapy: obstacles and opportunities. *Trends Immunol*. (2019) 40:511–23. doi: 10.1016/j.it.2019.04.002

19. Puliga E, Corso S, Pietrantonio F, Giordano S. Microsatellite instability in Gastric Cancer: Between lights and shadows. *Cancer Treat Rev*. (2021) 95:102175. doi: 10.1016/j.ctrv.2021.102175

20. Ding P, Liu P, Meng L, Zhao Q. Mechanisms and biomarkers of immune-related adverse events in gastric cancer. *Eur J Med Res*. (2023) 28:492. doi: 10.1186/s40001-023-01365-3

21. Wu Y-X, Zhou X-Y, Wang J-Q, Chen G-M, Chen J-X, Wang R-C, et al. Application of immune checkpoint inhibitors in immunotherapy for gastric cancer. *Immunotherapy*. (2023) 15:101–15. doi: 10.2217/imt-2022-0080

22. Zhang J, Gao A, Wang S, Sun Y, Wu J, Wang D, et al. Correlation between immune-related adverse events and efficacy of PD-(L)1 inhibitors in small cell lung cancer: a multi-center retrospective study. *Respir Res*. (2024) 25:256. doi: 10.1186/s12931-024-02890-3

23. Yu Y, Chen N, Yu S, Shen W, Zhai W, Li H, et al. Association of immune-related adverse events and the efficacy of anti-PD-(L)1 monotherapy in non-small cell lung cancer: adjusting for immortal-time bias. *Cancer Res Treat*. (2024) 56:751–64. doi: 10.4143/crt.2023.1118

24. Olsson Ladjevardi C, Koliadi A, Rydén V, El-Naggar AI, Digkas E, Valachis A, et al. Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness. *Front Oncol*. (2024) 14:1399171. doi: 10.3389/fonc.2024.1399171

25. Hao W, Liu W, Chang R, Yang M, Xin K, Liu J, et al. Safety and clinical efficacy of immune checkpoint inhibitors in advanced gastric cancer in the real world. *J Cancer Res Clin Oncol*. (2024) 150:180. doi: 10.1007/s00432-024-05703-8

26. Fukushima T, Kobayashi S, Ueno M. The correlation between immune-related adverse events and efficacy of immune checkpoint inhibitors. *Jpn J Clin Oncol*. (2024) 54:949–58. doi: 10.1093/jjco/hyae067

27. Zhang X, Xu S, Wang J, Lv Y, Wang N, Lai R, et al. Are anti-PD-1-associated immune related adverse events a harbinger of favorable clinical prognosis in patients with gastric cancer? *BMC Cancer*. (2022) 22:1136. doi: 10.1186/s12885-022-10199-x

28. Gumusay O, Callan J, Rugo HS. Immunotherapy toxicity: identification and management. *Breast Cancer Res Treat*. (2022) 192:1–17. doi: 10.1007/s10549-021-06480-5

29. Wang Y, Ertl C, Schmitt C, Hammann L, Kramer R, Grabmaier U, et al. Stringent monitoring can decrease mortality of immune checkpoint inhibitor induced cardiotoxicity. *Front Cardiovasc Med*. (2024) 11:1408586. doi: 10.3389/fcvm.2024.1408586

30. Hasan Ali O, Diem S, Markert E, Jochum W, Kerl K, French LE, et al. Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer. *OncoImmunology*. (2016) 5:e1231292. doi: 10.1080/2162402X.2016.1231292

31. Dougan M, Luoma AM, Dougan SK, Wucherpfennig KW. Understanding and treating the inflammatory adverse events of cancer immunotherapy. *Cell*. (2021) 184:1575–88. doi: 10.1016/j.cell.2021.02.011

32. Sullivan RJ, Weber JS. Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies. *Nat Rev Drug Discovery*. (2022) 21:495–508. doi: 10.1038/s41573-021-00259-5

33. Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. *Clin Cancer Res*. (2016) 22:886–94. doi: 10.1158/1078-0432.CCR-15-1136

34. Yamaguchi A, Saito Y, Narumi K, Furugen A, Takekuma Y, Shinagawa N, et al. Association between skin immune-related adverse events (irAEs) and multisystem irAEs during PD-1/PD-L1 inhibitor monotherapy. *J Cancer Res Clin Oncol*. (2023) 149:1659–66. doi: 10.1007/s00432-022-04425-z

35. Masuda K, Shoji H, Nagashima K, Yamamoto S, Ishikawa M, Imazeki H, et al. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab. *BMC Cancer*. (2019) 19:974. doi: 10.1186/s12885-019-6150-y

36. Lin J-X, Desiderio J, Lin J-P, Wang W, Tu R-H, Li P, et al. Multicenter validation study of the american joint commission on cancer (8th edition) for gastric cancer: proposal for a simplified and improved TNM staging system. *J Cancer*. (2020) 11:3483–91. doi: 10.7150/jca.36891

37. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer*. (2009) 45:228–47. doi: 10.1016/j.ejca.2008.10.026

38. Niu C, Zhu K, Zhang J, Joshi U, Liu H, Zahid S, et al. Analysis of immune-related adverse events in gastrointestinal Malignancy patients treated with immune checkpoint inhibitors. *Int J Cancer*. (2024) 154:1261–71. doi: 10.1002/ijc.34813

39. Wang H, Chen J, Gao W, Wu Y, Wang X, Lin F, et al. Construction of a nomogram with IrAE and clinic character to predict the survival of advanced G/GEJ adenocarcinoma patients undergoing anti-PD-1 treatment. *Front Immunol*. (2024) 15:1432281. doi: 10.3389/fimmu.2024.1432281

40. Zhang Y-J, Tian Q-Y, Wang C-E. Association between immune-related adverse events and the prognosis of patients with gastric cancer treated with nivolumab: a meta-analysis. *Front Oncol*. (2024) 14:1408755. doi: 10.3389/fonc.2024.1408755

41. Hara Y, Baba Y, Toihata T, Harada K, Ogawa K, Iwatsuki M, et al. Immune-related adverse events and prognosis in patients with upper gastrointestinal cancer treated with nivolumab. *J Gastrointest Oncol*. (2022) 13:2779–88. doi: 10.21037/jgo-22-281

42. Nishimura T, Fujimoto H, Fujiwara T, Ito K, Fujiwara A, Yuda H, et al. Impact of immune-related adverse events on survival outcomes in extensive-stage small cell lung cancer patients treated with immune checkpoint inhibitors. *Cancer Med*. (2024) 13:e7188. doi: 10.1002/cam4.7188

43. Immune-related adverse events associated with immune checkpoint blockade. *N Engl J Med*. (2018) 378:158–68. doi: 10.1056/NEJMra1703481

44. Groha S, Alaiwi SA, Xu W, Naranbhai V, Nassar AH, Bakouny Z, et al. Germline variants associated with toxicity to immune checkpoint blockade. *Nat Med*. (2022) 28:2584–91. doi: 10.1038/s41591-022-02094-6

45. Issaoui H, Ricci J. IL-7 germline variant: setting the stage for immune-related adverse events. *Mol Oncol*. (2023) 17:384–6. doi: 10.1002/1878-0261.13392

46. Hu W-T, Zhang Q, Zhang Z, He X, Zhou M, Guo Y, et al. Eosinophil and IFN-γ associated with immune-related adverse events as prognostic markers in patients with non-small cell lung cancer treated with immunotherapy. *Front Immunol*. (2023) 14:1112409. doi: 10.3389/fimmu.2023.1112409

47. Karachaliou N, Gonzalez-Cao M, Crespo G, Drozdowskyj A, Aldeguer E, Gimenez-Capitan A, et al. Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients. *Ther Adv Med Oncol*. (2018) 10:1758834017749748. doi: 10.1177/1758834017749748

48. Wang M, Zhai X, Li J, Guan J, Xu S, Li Y, et al. The role of cytokines in predicting the response and adverse events related to immune checkpoint inhibitors. *Front Immunol*. (2021) 12:670391. doi: 10.3389/fimmu.2021.670391

49. Jin Y, Chen D-L, Wang F, Yang C, Chen X-X, You J, et al. The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors. *Mol Cancer*. (2020) 19:154. doi: 10.1186/s12943-020-01274-7

50. Zhang Y, Cheng S, Zou H, Han Z, Xie T, Zhang B, et al. Correlation of the gut microbiome and immune-related adverse events in gastrointestinal cancer patients treated with immune checkpoint inhibitors. *Front Cell Infect Microbiol*. (2023) 13:1099063. doi: 10.3389/fcimb.2023.1099063

51. Ma J, Wei Q, Cheng X, Zhang J, Zhang Z, Su J. Potential role of gut microbes in the efficacy and toxicity of immune checkpoints inhibitors. *Front Pharmacol Frontiers;*. (2023) 14:1170591. doi: 10.3389/fphar.2023.1170591

52. Yousefi Y, Baines KJ, Maleki Vareki S. Microbiome bacterial influencers of host immunity and response to immunotherapy. *Cell Rep Med*. (2024) 5:101487. doi: 10.1016/j.xcrm.2024.101487

53. Yu X, Zhang X, Yao T, Zhang Y, Zhang Y. Fatal adverse events associated with immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis. *Front Med*. (2021) 8:627089. doi: 10.3389/fmed.2021.627089

54. Wang SJ, Dougan SK, Dougan M. Immune mechanisms of toxicity from checkpoint inhibitors. *Trends Cancer*. (2023) 9:543–53. doi: 10.1016/j.trecan.2023.04.002

55. Altan M, Li Q-Z, Wang Q, Vokes NI, Sheshadri A, Gao J, et al. Distinct patterns of auto-reactive antibodies associated with organ-specific immune-related adverse events. *Front Immunol*. (2023) 14:1322818. doi: 10.3389/fimmu.2023.1322818

56. Wang J, Ma Y, Lin H, Wang J, Cao B. Predictive biomarkers for immune-related adverse events in cancer patients treated with immune-checkpoint inhibitors. *BMC Immunol*. (2024) 25:8. doi: 10.1186/s12865-024-00599-y

57. Yang L, Murthy S, Cortellini A, Lim EA, Gonzalez M, Pinato DJ, et al. Effects of immune checkpoint inhibitor associated endocrinopathies on cancer survival. *Front Endocrinol*. (2024) 15:1369268. doi: 10.3389/fendo.2024.1369268

58. Baral P, Udit S, Chiu IM. Pain and immunity: implications for host defence. *Nat Rev Immunol*. (2019) 19:433–47. doi: 10.1038/s41577-019-0147-2

59. Meixiong J, Anderson M, Limjunyawong N, Sabbagh MF, Hu E, Mack MR, et al. Activation of mast-cell-expressed mas-related G-protein-coupled receptors drives non-histaminergic itch. *Immunity*. (2019) 50:1163–1171.e5. doi: 10.1016/j.immuni.2019.03.013

60. Khan Z, Hammer C, Carroll J, Di Nucci F, Acosta SL, Maiya V, et al. Genetic variation associated with thyroid autoimmunity shapes the systemic immune response to PD-1 checkpoint blockade. *Nat Commun*. (2021) 12:3355. doi: 10.1038/s41467-021-23661-4

61. Bai X, Kim MS, Kasumova G, Chen T, Cohen JV, Lawrence DP, et al. Predictable early onset high-dose-glucocorticoid-associated-irAE and its predictive role in anti-PD-1 monotherapy treated advanced melanoma patients. *J Clin Oncol*. (2019) 37:9544. doi: 10.1200/JCO.2019.37.15_suppl.9544